24 results about "Rectal adenoma" patented technology

The present invention discloses the use of the biomarker UGT2B15 in the diagnosis of colorectal adenoma. The present invention provides the use of a biomarker for diagnosing or predicting colorectal adenoma or / and a detection reagent thereof in the preparation of a product for diagnosing or predicting colorectal adenoma. The present invention provides a kit for diagnosing colorectal adenoma or predicting colorectal adenoma in a subject. The present invention provides an electronic device for diagnosing colorectal adenoma or predicting colorectal adenoma. The present invention provides a screening method for a biomarker for diagnosing or predicting colorectal adenoma, a method for constructing a diagnostic model for colorectal adenoma, and a processor, a computer medium, and a device.

The invention discloses a system and equipment for predicting colorectal cancer and progression thereof. Based on the found expression level difference of AXIN2 and / or EPHB2 in colorectal cancer and the progression thereof, the invention provides a colorectal cancer and progression prediction method, system and equipment, a computer readable storage medium and a computer program product, high-risk groups can be efficiently and accurately screened out from common groups, and colonoscopy is further completed in time. While the economic burden caused by endoscopic screening is relieved, patients suffering from colorectal adenoma and early colorectal cancer are screened out, and the method has great significance in early diagnosis and treatment of colorectal tumor and further remarkable reduction of the morbidity and mortality of colorectal cancer.

In various aspects and embodiments, the Disclosure provides methods for evaluating subjects for the presence or absence of colorectal neoplasms, such as colorectal cancer (CRC), colorectal adenoma (CRA), and progressive colorectal adenoma (CRAA), by metagenomic and multi-omics analysis of feces or other biological samples. In other aspects, the Disclosure provides methods for generating machine learning models or “signatures” based on metagenomic and multi-omics analysis of feces or other biological samples to evaluate subjects for the presence or absence of colorectal diseases, including but not limited to CRC, CRA, and CRAA.

The invention discloses a colorectal adenoma screening method based on serum metabolites, and belongs to the field of biomedical detection. The method comprises the steps of serum sample pretreatment, instrument analysis, quantitative analysis and prediction model construction, after 15-25 [mu] L of a serum sample is treated, 41 serum metabolites, age, gender and BMI are combined, and a LightGBM model is used for predicting the disease probability and performing layered suggestion. The kit fills up related gaps, has the advantages of non-invasiveness, high sensitivity and specificity, portability, high efficiency, low cost and the like, and is suitable for large-scale screening.

The present invention belongs to the technical field of diagnosis, and particularly relates to a marker for differentiating carcinomas of the colon and rectum from adenomas of the colon and rectum and the use thereof. Disclosed in the present invention is one or more of 75 markers as a marker for distinguishing carcinomas of the colon and rectum from adenomas of the colon and rectum. By means of detecting the content, expression level, and / or activity of the above markers, differentiation of carcinomas of the colon and rectum from adenomas of the colon and rectum can be achieved.

The invention discloses an application of a metabolite level detection reagent in preparation of a diagnostic kit for adenoma in a colorectal progression stage. A metabolite is selected from the group consisting of tridecane diacid, methyl 1-(methyl sulfur) propyl disulfide, histidine proline amide, termite dialdehyde, N-acetylglycine, 5-hydroxycaprin, arginyl glutamine, nalmefene and sodium alginate. The compound is selected from at least one of dialaphos and dipifolin. According to the invention, 11 kinds of differential metabolites which change continuously in the colorectal lesion progress process are screened from the serum exosome, and the 11 kinds of metabolites have good identification capability on the stage of colorectal lesion, and have good application prospects in screening and diagnosis of adenoma and colorectal cancer in the colorectal progression stage. And the method has great clinical significance in distinguishing the malignant degree of colorectal adenoma.

Methods of treating colorectal cancer or colorectal adenoma, diagnosing colorectal cancer or colorectal adenoma, monitoring treatment in a patient having colorectal cancer or colorectal adenoma, and monitoring risk for developing colorectal cancer or colorectal adenoma in patients can be accomplished through the use of RNA biomarkers, such as let-7c, miR-100, miR-lOb, miR-1246, miR-1290, miR-135b, miR-150p, miR-184, miR-199b, miR-200a, miR-203a, miR- 205, miR-20a, miR-433. miR-455. miR-543, miR-9, miR-18a, miR-19a, miR-4488, miR-107, miR-1228, miR-1229, miR-1323, miR-141, miR-142, miR-1538, miR-17, miR-195, miR-19b, miR-200b, miR-296, miR-34a, miR-3913, miR-5193, and miR-877.

The invention discloses a colorectal tumor risk prediction model based on a DKK4 gene and application thereof, and a construction method of the prediction model comprises the following steps: (1) determining the DKK4 gene as a candidate target through a differential expression gene screened by a public database; (2) evaluating the expression level and the biological function of DKK4 in colorectal cancer and precancerous lesions and the relevance with a Wnt signal channel by utilizing single gene function analysis and combining with a TCGA database; (3) through LASSO regression analysis, constructing a colorectal cancer risk scoring model by using DKK4 and related genes thereof, and screening candidate genes; and (4) verifying the prediction efficiency of the risk scoring model on the one-year and three-year lifetime of the colorectal cancer patient by using an independent data set, and verifying the expression difference of DKK4 in colorectal adenoma and cancer tissues through immunohistochemistry. The DKK4 can be used as a precancerous lesion specific marker, and the expression level of the DKK4 is in positive correlation with the risk of malignant adenoma transformation. The model can effectively evaluate the colorectal cancer progression risk.

The invention belongs to the technical field of biological medicine, and particularly relates to application of vitamin B12 in preparation of an auxiliary therapeutic agent for preventing or treating colorectal cancer precancerous lesions. The invention aims to solve the technical problem of providing a novel prevention and intervention means for colorectal cancer (CAC) caused by the cancerization process of colorectal adenoma and inflammatory atypical hyperplasia. The invention further provides a preparation method of the novel prevention and intervention means for the colorectal cancer caused by the cancerization process of the colorectal adenoma and the inflammatory atypical hyperplasia of the colorectal adenoma and the colorectal cancer caused by the inflammatory atypical hyperplasia of the colorectal adenoma. In a colorectal adenoma canceration process, the level of vitamin B12 in a circulatory system is reduced along with the development of diseases. In inflammatory and hereditary colorectal cancer mouse models, MHC-II signals can be enhanced by supplementing medicine vitamin B12, and CD4 effect memory T cell immunity can be reactivated. The invention provides a new thought for further researching the immune recovery strategy in the colorectal cancer precancerous lesion process and the medical application of the vitamin B12.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for preventing and treating colorectal adenoma and a preparation method and application thereof. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 10-20 parts of rhizoma pinellinae praeparata, 8-15 parts of scutellaria baicalensis, 5-10 parts of coptis chinensis, 8-15 parts of ginger, 5-15 parts of honey-fried licorice root, 5-15 parts of radix pseudostellariae, 10-20 parts of radix clematidis, 5-15 parts of dark plum, 25-35 parts of oyster, 10-20 parts of oldenlandia diffusa, 15-25 parts of wild buckwheat, 5-15 parts of pseudobulbus cremastrae seu pleiones, 10-20 parts of fiveleaf akebia fruit, 5-15 parts of curcuma zedoary, 15-25 parts of rhizoma smilacis glabrae and 3-8 parts of jujube. The traditional Chinese medicine composition is suitable for colorectal adenoma prevention and treatment and intervention of alimentary canal dysplasia and intraepithelial neoplasia, the clinical curative effect is definite, the recurrence rate of adenoma can be remarkably reduced, and a precise prevention and treatment system which takes dampness clearing and food retention removing as the core and takes cold and heat as well as six depression into consideration is constructed.

The invention belongs to the technical field of diagnosis, and particularly relates to a colorectal adenoma related marker and application thereof. The invention discloses one or more of 45 markers as the markers for screening, diagnosis, monitoring, curative effect evaluation or prognosis evaluation of the colorectal adenoma for the first time, and the screening, diagnosis, monitoring, curative effect evaluation or prognosis evaluation of the colorectal adenoma can be realized by detecting the content, expression quantity and / or activity of the markers.

The invention relates to a pharmaceutical composition for colorectal adenoma and application thereof. The pharmaceutical composition comprises at least one of the following components: a compound 1 and / or a pharmaceutically acceptable salt thereof; compound 2 and / or a pharmaceutically acceptable salt thereof; compound 3 and / or a pharmaceutically acceptable salt thereof; and a compound 4 and / or a pharmaceutically acceptable salt thereof, which can be used for treating and / or preventing diseases or conditions mediated by TNF-alpha. Target spots and active ingredients of the traditional Chinese medicine compound are determined through a network pharmacology research method, and the method has important application significance for guiding research and development of the traditional Chinese medicine compound.

The invention discloses an application of shewanella algal in promoting colorectal adenoma ferroptosis, and relates to the technical field of biology, the shewanella algal is Shewanella algal, the preservation number of the strain is BNCC386875, and the strain is preserved in the Henan Province Industrial Microbial Strain Engineering Technology Research Center. According to the application disclosed by the invention, the Shewanella algal BNCC386875 is determined for the first time and can promote colorectal adenoma ferroptosis, the action mechanism of the strain in the occurrence and development of colorectal adenoma is determined by regulating and controlling ferroptosis related protein expression and mitochondrial morphological change, and a new microbiological target is provided for etiological research of colorectal adenoma.

This invention discloses a biomarker for distinguishing between colorectal cancer and colorectal adenoma and its application, relating to the field of biomedical technology. The biomarker is selected from any one of the following: an exosome surface-driven biomarker composed of SELL, CD177, ITGAL, OLR1, B2M, and LAG3; an internal core protein composed of TGM3, PSMB4, KRT80, KRT2, DSG1, CPOX, CPN1, SUB1, LSM2, RAB34, PZP, SERPINA5, HYDIN, and PGLYRP1; or a single-indicator biomarker, KRT80. This invention enables the detection of colorectal cancer and colorectal adenoma.

The invention relates to the field of traditional Chinese medicines, and provides a traditional Chinese medicine composition for preventing colorectal adenomatous polyp, which is prepared from the following traditional Chinese medicines in parts by weight: 10-15 parts of fried white hyacinth bean, 10-15 parts of codonopsis pilosula slice, 12-18 parts of bran-fried bighead atractylodes rhizome, 10-15 parts of poria cocos, 5-8 parts of honey-fried licorice root, 20-30 parts of Chinese yam, 20-30 parts of coix seed, 2-5 parts of raw fructus amomi, 12-18 parts of oldenlandia diffusa, 12-18 parts of sculellaria barbata and 7-12 parts of vinegar-processed curcuma zedoary. And 2-4 parts of raw rhizoma coptidis tablets. In combination with the pathogenesis characteristics of spleen deficiency, dampness stasis and internal stagnation of turbid toxin of colorectal adenoma, the traditional Chinese medicine composition treats both symptoms and root causes, combines the whole and local parts, strengthens the spleen, replenishes qi, mobilizes the vital qi basis of the human body, clears away heat and toxic materials, and removes stasis to dissipate stagnation, so that local lesions of the adenoma are specifically solved.

The present invention provides compositions comprising fosfomycin for reducing or eliminating bacteria that promote the development of colorectal cancer in colorectal adenomas, polyps, and adenocarcinomas, and associated bacterial biofilms, by topical administration into the intestinal lumen.

The application belongs to the biological field and particularly relates to application of organic medlar polysaccharide in prevention and treatment of colorectal adenoma type polyps. Through in-vivo animal experiments, it is found that compared with common medlar polysaccharide, the organic medlar polysaccharide can significantly reduce the lesion area of the colorectal adenoma type polyps, can be used as a natural preparation for preventing and treating the colorectal adenoma type polyps, can effectively improve the colorectal adenoma type polyps, and can be used for reducing the incidence and progression risk of the colorectal adenoma type polyps.

A group of diagnostic biomarkers usable for diagnosis of colorectal cancer or advanced colorectal adenoma (CRC / ACRA) is provided. The method for detecting CRC / ACRA using the group of diagnostic biomarkers is also provided. For example, the method is a non-invasive approach that may utilize serum samples for detecting colorectal cancer. Moreover, the method for detecting colorectal cancer may detect colorectal cancer of different stages (e.g., pre-cancer stage, early stage, middle stage, late stage). A kit for detecting CRC / ACRA is also provided.

The application discloses application of a biomarker CCL26 in diagnosis of colorectal adenoma, and provides application of a substance for detecting a marker in a to-be-detected sample in preparation of a product for diagnosis or auxiliary diagnosis, prediction or auxiliary prediction of colorectal adenoma, and further provides related products, a risk prediction model, and an auxiliary diagnosis system and a scoring device. The CCL26 marker disclosed by the application has high sensitivity and specificity in diagnosis of colorectal adenoma, can identify colorectal adenoma in an early stage, and has high diagnosis efficiency.

Disclosed in the present invention are 45 markers related to colorectal adenoma, including one or more of TMPRSS15, ADGRE1, ADGRE5, AFM, APCS, BLNK, CABP2, CASP7, CCL25, CLIC5, COMP, ENPP2, F12, FASLG, FCER2, FCRL1, GAMT, GIP, HS3ST3B1, IGFBP1, IL4R, INPP1, ITPA, KAZN, KLK3, LPL, LSM1, LTA4H, MRPS16, NFASC, NOTCH3, NTF3, PAIP2B, PPY, PRAME, SERPING1, SOD3, SOST, SPINT3, STX7, SULT2A1, SWAP70, TEX101, YJU2 and ZCCHC8. By means of detecting the content, expression level and / or activity of the markers described above, the screening, diagnosis, monitoring, efficacy evaluation or prognosis evaluation of colorectal adenoma can be realized.

The present invention belongs to the technical field of learning model construction, and provides a semantic segmentation deep learning system and construction method for colorectal adenoma identification, including: a data set acquisition and processing module, which is used to acquire and process case images of colorectal adenoma to obtain a target data set; a model construction module, which is used to construct a semantic segmentation deep learning model that obtains H&E adversarial average teacher based on a dye called hematoxylin and eosin in combination with a semi-supervised learning model; and a model learning and training module, which is used to learn and train the semantic segmentation deep learning model based on the target data set. The present invention can ensure the creation quality of the semantic segmentation deep learning system for colorectal adenoma identification by acquiring and processing case images of colorectal adenoma, and based on a dye called hematoxylin and eosin in combination with a semi-supervised learning model, construct and learn and train a semantic segmentation deep learning model, thereby providing a basis for efficiently and accurately identifying case images of colorectal adenoma.

The invention belongs to the technical field of diagnosis, and particularly relates to a marker for distinguishing colorectal cancer and colorectal adenoma and application of the marker. The invention discloses one or more of 75 markers as the marker for distinguishing the colorectal cancer and the colorectal adenoma for the first time, and the colorectal cancer and the colorectal adenoma can be distinguished by detecting the content, the expression quantity and / or the activity of the marker.

The application belongs to the technical field of computer hospital, and particularly relates to a method for establishing an early diagnosis model of intestinal adenocarcinoma based on peripheral blood detection, which comprises the following steps: collecting serum samples; detecting by using a Raman spectrometer; performing graphic analysis and data processing on the collected Raman spectrum signals; and constructing a deep learning model architecture. The application successfully constructs a natural language model suitable for Raman spectrum data processing and analysis, and further constructs a recognition model of patients with colorectal adenoma and adenocarcinoma. The application successfully develops a screening method for colorectal adenoma and adenocarcinoma based on peripheral blood Raman spectrum detection.

On the basis of LC-MS / MS targeted absolute quantitative detection analysis, a training set is established through a human plasma sample to screen metabolites related to colorectal adenoma-colorectal cancer, a model is established through a machine learning algorithm, 13 metabolites are screened from 33 metabolites, the AUC value of the combination of 13 compounds reaches 0.8 or above, and the AUC value of the combination of 13 compounds reaches 0.8 or above. The result shows that the combination of 13 compounds has very high risk assessment value for CRA and CRC. The marker combination disclosed by the invention can effectively identify CRA and CRC patients and is high in sensitivity and good in specificity, and the detection method is high in accuracy, high in flux, low in price, high in subject acceptance degree and suitable for popularization and application.